This trial is evaluating whether Durvalumab will improve 1 primary outcome and 4 secondary outcomes in patients with Mesothelioma. Measurement will happen over the course of From randomization until end of treatment, up to 15 months.
This trial requires 55 total participants across 2 different treatment groups
This trial involves 2 different treatments. Durvalumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Results from a recent clinical trial suggest that mesotheliomas may develop from asbestos-induced malignant mesothelioma or may arise from the malignant transformation of malignant adenocarcinoma with mixed mesenchymal differentiation. The development of lung cancers from pleural mesothelioma also requires a pleural precursor.
Patients with malignant pleural mesothelioma most commonly present with cough. In the absence of coughing the chest X-ray is a less useful exam. Chest radiography and CT of the chest can detect pleural malignancies and may be recommended in the work-up of patients with pleural effusion. The most reliable exam is chest CT where it is often the first choice.
The survival outcomes show the need for a new treatment strategy for mesothelioma, such as increased dose and novel chemotherapy regimens. With careful evaluation of this disease subtype and its rarity, there may indeed be a chance to find patients who could potentially benefit from the novel chemotherapy regimens. If future trials confirm this and/or show greater survival outcomes, then we could consider abandoning the current standard of care chemotherapies, which, at present, appear to work only in a subset of patients.
Mesothelioma is an aggressive cancer of the mesothelium which is generally thought to be under-recognized. We have shown why this cancer is less well understood, but we have highlighted the importance of studying this cancer as it continues to claim its victims every year.
The two main lines of chemotherapy used for mesothelioma are platinum-based combinations. The addition of gemcitabine to chemotherapy offers patients a greater chance of survival. For malignant pleural mesothelioma, a combination of chemotherapy with intrapleural hyperthermic perfusion therapy (IPHPT) followed by surgery and adjuvant chemotherapy improves survival. A multidisciplinary approach is also preferred for small, early mesothelioma. Radiation therapy can also be applied with good results, especially in the setting of localized disease.
As a whole, the average age at diagnosis of mesothelioma cases in U.S. is 64 years of age and the average age of death is 68 years of age. However, the average age of death is much lower than what could be explained on the basis of the average age at time of diagnosis which is 61 years.
mesothelioma is a deadly cancer. Mesothelioma was identified on October 19, 2004. A report in the Journal of the American Society For Clinical Oncology published this result. A study of the National Cancer Institute of the National Library of Medicine at the National Institutes of Health released two major findings. Mesothelioma is a rare cancer. Mesothelioma can occur in people who have never smoked. However, a link has been found between asbestos and mesothelioma in people who have smoked and have had exposure to airborne and/or insoluble fibers from asbestos. Mesothelioma is also related to long term exposure to asbestos fibers in the family.
At this time, there is no evidence that durvalumab is beneficial in treating patients with metastatic or locally advanced mesothelioma.Durvalumab, when used in combination with pembrolizumab or nivolumab, has a very good risk-benefit profile. There is strong evidence for its safety (i.e. no discernible adverse effects) in combination with pembrolizumab or nivolumab used for the treatment of metastatic pancreatic cancer. Given this information, further studies are justified to assess durvalumab's efficacy (i.e.
Recent findings, subjects receiving durvalumab had more than twice the frequency of subjects developing serious adverse events vs. subjects receiving placebo. In addition, subjects treated with durvalumab were three times as likely to have an infusion-related reaction as subjects treated with placebo.Durvalumab has been FDA approved to treat melanoma in patients 6 years of age and older with unresectable or metastatic uveal melanoma.\n\nAs of 2016, there are no curative treatments for mesothelioma. Instead, patients receive multimodality treatment. While chemotherapy may be used in initial treatment for early stages, treatment usually involves surgery in order to remove the cancer as often as possible.
For Stage 4, most of the patients’ health conditions and chemotherapy regimens improved their quality of life and made it possible for them to continue with daily activities. The doctors’ intervention enabled patients to spend more time, both with family and with friends, exercising, going to massages, clubs, and museums. This is particularly important for patients with an active social life, who are more likely to get stuck in their daily routines and become even more depressed and depressed in the long term if they have to miss such activities. Mesothelioma has an unpredictable growth pattern, meaning it can’t be determined whether the cancer will grow or shrink throughout the period of time that a patient is treated.
Durvalumab substantially improved quality of life in patients with metastatic/inoperable/progressive Mmeso compared with placebo. Recent findings may benefit patients through diminished pain, improved appetite, improved nutritional status, and decreased fatigue.